AU656914B2 - New peptides and their use - Google Patents
New peptides and their useInfo
- Publication number
- AU656914B2 AU656914B2 AU83985/91A AU8398591A AU656914B2 AU 656914 B2 AU656914 B2 AU 656914B2 AU 83985/91 A AU83985/91 A AU 83985/91A AU 8398591 A AU8398591 A AU 8398591A AU 656914 B2 AU656914 B2 AU 656914B2
- Authority
- AU
- Australia
- Prior art keywords
- glu
- ile
- amino acid
- peptide
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 58
- 102000004196 processed proteins & peptides Human genes 0.000 title description 24
- 241000223960 Plasmodium falciparum Species 0.000 claims abstract description 49
- 201000004792 malaria Diseases 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 14
- 229960005486 vaccine Drugs 0.000 claims abstract description 13
- 230000036039 immunity Effects 0.000 claims abstract description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- 238000002255 vaccination Methods 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 108091007433 antigens Proteins 0.000 description 29
- 210000003743 erythrocyte Anatomy 0.000 description 23
- 244000045947 parasite Species 0.000 description 23
- 230000009257 reactivity Effects 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 18
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 10
- 101150089906 resA gene Proteins 0.000 description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 101710175243 Major antigen Proteins 0.000 description 6
- 241000224016 Plasmodium Species 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 208000030852 Parasitic disease Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 235000014393 valine Nutrition 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 101710169678 Histidine-rich protein Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 208000009182 Parasitemia Diseases 0.000 description 2
- -1 Polyethylene Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003936 merozoite Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101100012910 Plasmodium falciparum (isolate FC27 / Papua New Guinea) FIRA gene Proteins 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
PCT No. PCT/SE91/00541 Sec. 371 Date Apr. 8, 1993 Sec. 102(e) Date Apr. 8, 1993 PCT Filed Aug. 16, 1991 PCT Pub. No. WO92/03159 PCT Pub. Date Mar. 5, 1992A peptide comprising the amino acid sequence: U-O-X-glu-Z or O-X-glu-Z-ala-glu, wherein: U is an amino acid residue selected from val and ile; O is an amino acid residue selected from ala and thr: X is an amino acid residue selected from asp and glu: and Z is an amino acid residue selected from ile and val: the use of the peptide in the preparation of a vaccine; a composition for vaccination against malaria induced by Plasmodium falciparum, comprising such peptide in admixture with a pharmaceutically acceptable carrier; and a method of inducing immunity against malaria induced by Plasmodium falciparum, which comprises administering to a person in need of such immunity an effective amount of said composition.
Description
New peptides and their use.
The present invention relates to new peptides, their use as active ingredients in vaccines and compositions containing same.
BACKGROUND OF THE INVENTION
Malaria is a wide spread disease, particularly in the developing countries, and scientists are constantly looking for new means to control the dangerous parasitic disease caused by plasmodial parasites. Among these parasites Plasmodium falciparum causes the most severe disease, responsible for the major part of the mortality due to malaria.
One strategy in combatting malaria resides in the use of a conventional vaccine based on attenuated or dead malaria parasites, but such approach has not been found to be practically feasible.
The alternatives are constituted by development of modern techniques, such as the manufacture of proteins by chemical synthesis or by DNA technology, such proteins as components in subunit vaccines being able to induce
protective immunity against the parasite infection.
One strategy in the selection of antigenic sequences to be included in a potential subunit vaccine against Plasmodium falciparum malaria is to define the epitopes of antibodies which have the capacity to interfere with the parasite life cycle. Properly presented in immunogens these epitopes are expected to induce protective antibody responses. With regard to the asexual blood-stages of P . falciparum, the main attention in this context has been made to antibodies with capacity to inhibit merozoite reinvasion in vitro (Anders, R.F. (1985) Candidate antigens for an asexual blood-stage vaccine. Parasitol. Today 1, 152-155). However, antibodies which inhibit the cytoadherence of infected erythrocytes to endothelial cells (Howard, R.J. (1988) Malarial proteins at the membrane of Plasmodium falciparum-infected erythrocytes and their involvement in cytoadherence to endothelial cells. Prog. Allergy 41, 98-147; Udomsangpetch, R., Aikawa, M., Ber
zins, K. , Wahlgren, M. and Perlmann, P. (1989) Cytoadherence of knobless Plasmodium falciparum-infected erythrocytes and its inhibition by a human monoclonal antibody. Nature 338, 763-765) or inhibit rosette formation between uninfected and infected erythrocytes (Carlsson, J., Holmquist, G., Taylor, D.W., Perlmann, P. and Wahlgren, M. (1990) Antibodies to a histidine-rich protein (PfHRP1) disrupt spontaneously formed Plasmodium falciparum erythrocyte rosettes. Proc. Natl. Acad. Sci. USA 87, 2511-2515) may also be of interest. Such antibodies are expected to interfere in vivo with the sequestration of late-stage infected erythrocytes (Howard, R.J. (1988) Malarial proteins at the membrane of Plasmodium falciparum-infected erythrocytes and their involvement in cytoadherence to endothelial cells. Prog. Allergy 41, 98-147; Carlson, J., Holmquist, G., Taylor, D.W., Perlmann, P. and Wahlgren, M. (1990) Antibodies to a histidine-rich protein (PfHRP1) disrupt spontaneously formed Plasmodium falciparum erythrocyte rosettes. Proc.Natl.Acad. Sci. USA 87, 2511-2515).
The human monoclonal antibody (mAb) 33G2, obtained from an Epstein-Barr virus transformed B-cell originating from a Liberian P . falciparum-immune donor (Udomsangpetch, R., Lundgren, K ., Berzins, K., Wahlin, B., Perlmann, H., Troye- Blomberg, M., Carlsson, J., Wahlgren, M., Perlmann, P. and Bjorkman, A. (1986) Human monoclonal antibodies to Pf155, a major antigen of malaria parasite Plasmodium falciparum.
Science 231, 57-59) has several interesting biological properties. It inhibits both P . falciparum merozoite reinvasion in in vitro cultures (Udomsangpetch, R., Lundgren, K., Berzins, K., Wahlin, B., Perlmann, H., Troye-Blomberg , M, Carlsson, J., Wahlgren, M., Perlmann, P. and Bjorkman, A. (1986) Human monoclonal antibodies to Pf155, a major antigen of malaria parasite Plasmodium falciparum. Science 231, 57-59) as well as cytoadherence of infected erythrocytes to melanoma cells in vitro (Udomsangpetch, R., Aikawa, M., Berzins, K., Wahlgren, M. and Perlmann, P. (1989) Cytoadherence of knobless Plasmodium falciparum-infected erythrocytes and its in
hibition by a human monoclonal artibody. Nature 338, 703-765). The mAb , thus, has the capacity to interfere with the parasite erythrocytic life cycle at two potential target sites for protective antibodies in vivo (Anders, R.F. (1985) Candidate antigens for an asexual blood-stage vaccine. Parasitol. Today 1, 152-155) which makes the epitope recognized by the mAb of great interest with regard to vaccine development.
The mAb 33G2 was initially selected due to its reactivity with Pf155/RESA as detected by erythrocyte membrane immunofluorescence (EMIF) and immunoblotting (Udomsangpetch, R., Lundgren, K., Berzins, K., Wihlin, B., Perlmann, H., Troye-Blomberg, M. , Carlsson, J., Wahlgren, M., Perlmann, P. and Bjorkman, A. (1986) Human monoclonal antibodies to Pf155, a major antigen of malaria parasite Plasmodium falciparum.
Science 231, 57-59) but subsequent analyses with recombinant fusion proteins and synthetic peptides revealed that the antibody showed reactivity with a family of cross-reacting P . falciparum blood-stage antigens, including Pf155/RESA, Pf11.1 and Ag332 (Mattei, D., Berzins, K., Wahlgren, M.,
Udomsangpetch, R., Perlmann, P., Griesser, H.W., Scherf, A., Muller-Hill, B., Bonnefoy, S., Guilotte, M., Langsley, G., Pereira da Silva, L. and Mercereau-Puijalon, 0. (1989) Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens. Parasite Immunol. 11, 15-30; Mercereau-Pui jalon, 0., Langsley, G., Mattei, D., Guilotte, M., Blisnick, T., Berzins, K., Griesser, H.W., Scherf, A., Muller-Hill, B. and Pereira da Silva, L. (1987) Presence of cross-reacting determinants on several blood-stage antigens of Plasmodium falciparum. UCLA Symp.Molec. Cell. Biol. 42, 343354; Udomsangpetch, R., Carlsson, J.,
Wahlin, B., Holmquist, G., Ozaki, L.S., Scherf, A., Mattei, D., Mercereau-Puijalon, 0., Uni, S., Aikawa, M., Perzins, K. and Perlmann, P. (1989) Reactivity of the human monoclonal antibody 33G2 with repeated sequences of three distinct Plasmodium falciparum antigens. J. Immunol. 142, 3620-3626). A
feature shared between these antigens is their contents of several tandemly repeated amino acid sequences containing regularly spaced pairs of glutamic acid (Mattei, D., Berzins, K., Wahlgren, M., Udomsangpetch, R., Perlmann, P., Griesser, H.W., Scherf, A., Muller-Hill, B., Bonnefoy, S., Guillotte, M., Langsley, G., Pereira da Silva, L. and Mercereau-Puijalon, 0. (1989) Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens. Parasite Immunol. 11, 15-30; Favaloro, J.M., Coppel, R.L., Corcoran, L.M., Foote, S.J., Brown, G.V., Anders, R.F. and Kemp, D.J. (1986) Structure of the RESA gene of Plasmodium falciparum. Nucleic Acids Res. 14, 8265-8277; Scherf, A., Hilbich, C., Sieg, K., Mattei, D., Mercereau-Puijalon, 0. and Miiller-Hill, B. (1988) The 11-1 gene of Plasmodium falciparum codes for distinct fast evolving repeats. EMB0 J. 7, 1129-1137).
These dimers of glutamic acid were suggested to be the structures responsible for the antigenic cross-reactions seen between the three antigens (Mattei, D., Berzins, K., Wahlgren, M., Udomsangpetch, R., Perlmann, P., Griesser, H.W., Scherf, A., Muller-Hill, B., Bonnefoy, S., Guilotte, M., Langsley, G., Pereira da Silva, L. and Mercereau-Puijalon, 0. (1989) Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens. Parasite Immunol. 11, 15-30; Merecereau-Puijalon, 0., Langsley, G., Mattei, D., Guilotte, M., Blisnick, T., Berzins, K., Griesser, H.W.,
Scherf, A., Muller-Hill, B. and Pereira da Silva, L. (1987) Presence of cross-reacting determinants on several blood-stage antigens of Plasmodium falciparum. UCLA Symp.Molec. Cell. Biol. 42, 343-354; Udomsangpetch, R., Carlsson, J., Wahlin, B., Holmquist, G., Ozaki, L.S., Scherf, A., Mattei, D., Mercereau-Puijalon, 0., Uni, S., Aikawa, M., Berzins, K. and Perlmann, P. (1989) Reactivity of the human monoclonal antibody 33G2 with repeated sequences of three distinct Plasmodium falciparum antigens. J. Immunol. 142, 3620-3626). Inhibition with synthetic peptides of the mAb 33G2 binding in
EMIF showed that peptides corresponding to Ag332 repeat se
que nces wo re the most efficient inhibitors, suggesting that Ag332 was the original target for the antibody (Udomsangpetch, R., Carlsson, J., Wahlin, B., Holmquist, G., Ozaki, L.S., Scherf, A., Mattei, D., Mercereau-Puijalon, O., Uni, S., Aikawa, M., Berrins, K. and Perlnann, D. (19f9) Reactivity of the human monoclonal antibody 33G2 with repeated sequences of three distinct Plasmodium falciparum antigens. J. Immunol. 142, 3620-3626).
The major object of the present invention is to provide new peptides capable of inducing immunity against malaria.
Another object of the invention is to provide new compositions for vaccination against malaria comprising such peptide.
Yet another object of the invention is to provide a method of inducing immunity against malaria.
SUMMARY OF THE INVENTION
It has been found that a peptide comprising the amino acid sequence:
U-O-X-glu-Z, wherein:
U is an amino acid residue selected from val and ile;
O is an amino acid residue selected from ala and thr;
X is an amino acid residue selected from asp and glu; and
2 is an amino acid residue selected from ile and val is capable of providing protective immunity against malaria induced by Plasmodium falciparum. Such protective immunity can be provided also by a peptide comprising the amino acid . sequence:
O-X-glu-Z-ala-glu, wherein
O, X and Z have the above meaning.
Preferred embodiments of the peptide of the present invention are the following:
glu-ser-val-thr-glu-glu-ile;
ser-val-thr-glu-glu-ile-ala;
val-thr-glu-glu-ile-ala-glu;
ser-val-thr-glu-glu-ile;
val-thr-glu-glu-ile-ala;
val-thr-glu-glu-ile;
ile-thr-glu-glu-ile;
val-ala-glu-glu-ile; and
ile-ala-asp-glu-ile.
Part icul arly preferred are the following peptides:
val-thr-glu-glu-ile,
thr-glu-glu-ile-ala-glu-glu, and
thr-glu-glu-ile-ala-glu.
Accordingly, the peptides of the present invention find medicinal use, particularly as acive ingredients in vaccines, such as vaccines against malaria.
The peptides of the present invention are also useful in the preparation of vaccines, particularly vaccines for combatting malaria induced by Plasmodium falciparum.
The invention also covers compositions for vaccination against malaria induced by Plasmodium falciparum, said composition comprising a peptide selected among those defined or mentioned above in admixture with a pharmaceutically acceptable carrier. It is preferred to use carriers suitable for parenteral administration.
As is generally known within immunology the immunogenic response resulting from administration of a relatively small peptide can be enhanced in several ways.
First, it is conceivable to contain the active peptide or principal in a larger molecule, wherein said peptide is present in repeating units. Such polymerized form can be prepared using recombinant DNA techniques.
Second, the peptide can be coupled to a macromolecular carrier, such as bovine serum albumin or other immunogenic
cerrier or ediuvant this inducing a better immune response against the peptide in view of the increased size of the molecule. The antigenic presentation of a small peptide in accordance with the invention can be improved for example by conjugation to a preformed iscom as a carrier (for details see Journal of Immunological Methods, 98 (1987) 137-143, K. Lofgren et al.).
The composition of the present invention can be constituted by a solution, a suspension or other form of preparation. Such solutions or suspension may take the form of sterilized aqueous isotonic preparations, such as isotonic saline solution or glucose solution. As indicated above parenteral administration is preferred.
It goes without saying that although the peptides of the invention can be used alone, combinations of two or more of same can be contained in one and the same composition.
Finally, the present invention provides a method of inducing immunity against malaria induced by Plasmodium falciparum. said method comprising administering to a person in need of such immunity an effective amount of the composition as defined above. The method is particularly exercised in the form of parenteral injection.
In the present disclosure the abbreviations used have the following meanings:
A = ala = alanine;
D = asp = aspartic acid;
C = cys = cysteine
E = glu = glutamic acid;
I = ile = isoleucine;
L = leu = leucine
K = lys = lysine
F = phe = phenylalanine
P = pro = proline
S = ser = serine
T = thr = threonine; and
W = trp = tryptophan
Y = tyr = tyrosine
V = val = val ine
EXAMPLES
The present invention will be described more detailed in the following specific examples. Said examples are not to be construed to limit the scope of the invention otherwise as defined in the appended claims. The examples are given with reference to the appended drawings, wherein:
Fig. 1 shows antibody reactivity of peptides according to the invention expressed as absorbance at 405 nm;
Fig. 2 shows antibody reactivity to peptides according to the invention also expressed as the absorbance at 405 nm;
Fig. 3 shows a replacement set analysis of 33G2 reactivity to an octapeptide; and
Fig. 4 shows antibody reactivity to epitope analogs expressed as the absorbance at 405 nm.
EXAMPLE 1
Establishment of a human B-cell line producing the monoclonal antibody 33G2.
Peri f eral blood lymnphocytes ( PBL ) were isolated by s tandard procedures from heparinized blood of a Liberian donor known to be immune to malaria (Udomsangpetch, R., Lundgren, K., Berzins, K., Wahlin, B., Perlmann, H., Troye-Blomberg, M., Carlsson, J., Wahlgren, M., Perlmann, P. and Bjorkman, A. (1986) Human monoclonal antibodies to Pfl55, a major antigen of malaria parasite Plasmodium falciparum. Science
231, 57-59). The PBL were incubated for 3 days with P .falciparum parasite extract in order to activate the malaria specific B-lymphocytes (Lundgren, K., Wahlgren, M., Troye-Blomberg, M., Berzins, K., Perlmann, H. and Perlmann, P. (1983) Monoclonal anti-parasite and ant i-RBC antibodies produced by stable EBV-transformed B cell lines from malaria patients. J . Immunol. 131, 2000-2003). For transformation of B-lymphocytes Epstein Barr virus (EBV), contained in culture medium from the EBV-producing marmoset cell line B95-8, was added to the PBL and incubated for 2hr at 37°C. After washing, the cells were suspended at 2× 106/ml in tissue culture medium
PPMI 1640 supplemented with 10% fetal calf serum, 1 % glutamine and 25μg/ml gentamicin) containing 0.2 u-g/ml of cyclosporin A and then incubated in 10 ml roundbottomed tubes for 5 days at 37°C in air + 5% CO2. The cells were then transferrad to 50 ml tissue culture flasks for continued propagation for 9 days. Cyclosporin was present in all media during the first 2 weeks of cell propagation. Two weeks after transformation, the cells were seeded in 96-well tissue culture plates with 5×l05 irradiated (4500 rad) allogeneic PBL per well as feeder cells. Immunoglobulin producing cultures were detected by measuring in enzyme linked immunosorbent assay (ELISA) (Engvall & Perlmann, Immunochemistry 8, 871-874, 1971) the presence in the culture medium of the wells of immunoglobulin. Immunoglobulin containing culture εupernatants were further analyzed for the presence of antibodies to the P . falciparum antigen Pf155/RESA by means of indirect immunofluorescence using glutaraldehyde fixed and air dried monolayers of infected erythrocytes from P . falciparum in vitro cultures (Perlmann et al. J.Exp.Med. 159, 1686-1704, 1984). Cultures scoring positive in the latter assay were submitted to repeated cloning by limited dilution. Monoclonality of the antibodies produced was assessed by isoelectric focusing. The antibody producing clone 33G2 thus obtained showed high growth rate and antibody production (10-15 μg IgM/ml in 72 hours) (Udomsangpetch, R., Lundgren, K., Berzins, K., Wahlin, B., Perlmann, H., TroyeBlomberg, M., Carlsson, J., Wahlgren, J., Perlmann, P. and Bjorkman, A. (1986) Human monoclonal antibodies to Pf155, a major antigen of malaria parasite
Plasmodium falciparum. Science 231, 57-59).
EXAMPLE 2
Inhibition in vitro of malaria parasite invasion into red blood cells.
The capacity of the monoclonal antibody (mAb) 33G2 to inhibit parasite development in P . falciparum in vitro cultures was assayed by a procedure described by Wahlin et al.
(Proc. Nat. Acad. Sci. USA 81, 7912-7916, 1984). P. falciparum cultures were diluted with normal 0+ erythrocytes to a parasitemia of 0.5% and a hematocrit of 2% .
Aliquots of the parasite suspension (100 μl) were seeded in quadruplicate in 96-well flat-bottomed microculture plates. The mAb 33G2 was added to the wells at differrent concentrations, either in culture supernatant or after purification on concanavalin A-Sepharose of ammonium sulfate precipitated culture supernatants (Kleine et al. Molec. Immunol. 16, 421-425, 1979). After incubation for 20 hr at 37°C in a candle jar (Trager & Jensen, Science 193, 673-675, 1976), the erythrocytes from each well were washed in tris-buffered Hanks solution (TH) and monolayers were prepared on eight-well multitest slides as follows. Erythrocyte suspensions were applied to slides treated with bicarbonate buffer (pH 9.6). Immediately after being washed in TH, the monolayers were fixed briefly (2×10 sec) in 1% glutaraldehyde in phosphate-buffered saline (pH 7.4), washed in distilled water and then air-dried extensively under a fan. The parasites were stained with acridine orange arid the number of parasitized erythrocytes was obtained by counting 4×104 erythorcytes per sample.
Both preparations of mAb 33G2 inhibited P . falciparum reinvasion efficiently in a concentration dependent manner, the culture supernatant contained mAb giving 50% inhibition of reinvasion at 14 μg/ml and the purified mAb giving 50% inhibition at 5.5 μg/ml (Udomsangpetch, R., Lundgren, K., Berzins, K., Wahlin, B., Perlmann, H., Troye-Blomberg, M., Carlsson, J., Wahlgren, M., Perlmann, P. and Bjorkman, A. (1986) Human monoclonal antibodies to Pf155, a major antigen of malaria parasite Plasmodium falciparum. Science 231, 57-59).
EXAMPLE 3
Inhibition of cytoadherence of malaria infected erythrocytes to endothelial and melanoma cells in vitro.
The capacity of mAb 33G2 to inhibit the cytoadherence
of P .falciparum infected erythrocyteε to endotneliai cells was demonstrated in an assay using the melanoma cell line C32 as described by Udeinya et al . (Exp. Parasitol. 56, 207-214, 1983). Melanoma cells grown on cover slips were fixed with 1% formaldehyde in phosphats-buff ared saline ( ph 7.4) and then stored at 4°C until used. A suspension (2% hematocrit) of erythrocytes from a P . falciparum culture, containing mainly trophozoites and schizonts at 5-10% parasitemia, were incubated with the fixed melanoma cells at room temperature on a rotating platform for 1 hour. Unbound erythrocytes were flushed away with phosphate-buffered saline. The coverslips were then fixed with 1% glutaraldehyde in phosphate-buffered saline, stained with Giemsa and examined in the light microscope. For assaying antibody mediated inhibition of cytoadherence, pellets of infected erythrocytes (40-50 μl) were suspended in 100 μl of antibody solution (15-250 μg/ml) and incubated for 30 min at 37°C with agitation every 10 min. The erythrocytes were then diluted to a 2% hemat oc r i t suspension and applied to the cytoadherence assay as described above. The number of bound erythrocytes per 100 melanoma cells was counted and expressed as the percentage of bound cells:
The mAb 33G2 inhibited cytoadherence in a dose dependent manner, giving about 45% inhibition at the highest antibody concentration tested (250 μg of purified mAb per ml) (Udomsangpetch, R., Aikawa, M., Berzins, K., Wahlgren, M. and Perlmann, P. (1989) Cytoadherence of knobless Plasmodium falciparum-infeeted erythrocytes and its inhibition by a human monoclonal antibody. Nature 338, 763-765) . EXAMPLE 4
Reactivity of monoclonal antibody 33G2 with cross-reactive P. falciparum antigens.
The mAb 33G2 was initially selected due to its reactivity with the P . falciparum antigen Pfl55/RESA as detected by immunofluorescence and immunoblotting (see Ex. 1 and ref. 1). Analysis of antibody reactivity with different recombinant
P . falciparum blood stage antigens was performed by immunoblotting using recombinant bacterial (E. coli) plaques (Mattei, D., Berzins, K., Wahlgren, M. , Udomsangpetch, R., Perlmann, P., Griesser, H.W., Scherf, A., Muller-Hill, B., Bonnefoy, S., Guillotte, M., Langsley, G., Pereira da Silva, L. and
Mercereau-Pui jalon, 0. (1989) Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens. Parasite Immunol. 11, 15-30). The mAb showed binding to bacterial plaques expressing parts of the P . falciparum antigens Pf11.1, Ag332 and Pf155/RESA, showing the strongest reactivity with Ag332 expressing plaques (Mattei, D., Berzins, K., Wahlgren, M., Udomsangpetch, R., Perlmann, P., Griesser, H.W., Scherf, A., Muller-Hill, B., Bonnefoy, S., Guillotte, M., Langsley, G., Pereira da Silva, L. and Mercereau-Puijalon, 0. ( 1989 ). Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens. Parasite Immunol. 11, 15-30). No binding was seen to bacterial plaques expressing the P . falciparum antigens FIRA or Ag281. The capacity of various synthetic peptides, corresponding to repeated sequences in the antigens
Pf11.1, Ag332 and Pf11/RESA, to block the binding of mAb 33G2 to Pf11/RESA as detected by immunofluorescence was analysed (Udomsangpetch, R., Carlsson, J., Wahlin, B., Holmquist, G., Ozaki, L.S., Scherf, A., Mattei, D., Mercereau-Puijalon, 0., Uni, S., Aikawa, M., Berzins, K. and Perlmann, P. (1989) Reactivity of the human monoclonal antibody 33G2 with repeated sequences of three di st inc t Plasmodium falciparum antigens. J . Immunol . 142, 3620-3626). Different concentrations of the peptides (up to 200 μg/ml) were mixed with a fixed concentration of the mAb, which then was used in the immunofluoresce assay (see Ex. 1). The peptide Y ( SVTEEIAEEDK) 2 , corresponding to a dimer of amino acids 2-12 in antigen Ag332 (Mattei, D., Berzins, K., Wahlgren, M., Udomsangpetch, R., Perlmann, P., Griesser, H.W., Scherf, A., Muller-Hill, B., Bonnefoy, S., Guillotte, M., Langsley, G., Pereira da Silva, L. and
Mercereau-Puijalon, 0. (1989) Cross-reactive antigenic deter
minants present on different Plasmodium falciarum blood-stage antigens. Parasite Immunol. 11, 15-30), was the most efficient inhibitor of mAb binding, giving complete inhibition of immunofluorescence at 0.2 μg/ml (Udomsangpetch, R., Carlrεon, J., Vahlin, B., Holmquist, G., Ozaki, L.S., Scherf, A., Mattei, D., Mercereau-Pui jalon , 0., Uni , S., Aikawa, M., Berzins, K. and Perlmann, P. (1989) Reactivity of the human monoclonal antibody 33G2 with repeated sequences of three distinct Plasmodium falciparum antigens. J . Immunol . 142, 3620-3626). Also some peptides corresponding to sequences in Pf11.1 and PF155/RESA inhibited mAb 33G2 immunofluorescence but with considerably less efficiency, the Pf11.1 peptide (EEVVEEVVP)2 and the Pf155/RESA peptide both giving complete inhibition at 100 μg/ml. The results show that mAb 33G2 recognizes a family of cross-reactive P . falciparum antigens including Pf11.1, Pf155/RESA and Ag332, the latter antigen being the optimal target for the mAb (Udomsangpetch, R., Carlsson, J., Wahlin, B., Holmquist, G., Ozaki, L.S., Scherf, A., Mattei, D., Mercereau-Puijalon , 0., Uni, S., Aikawa, M., Berzins, K. and Perlmann, P. (1989) Reactivity of the human monoclonal antibody 33G2 with repeated sequences of three distinct Plasmodium falciparum antigens. J . Immunol . 142, 3620-3626). EXAMPLE 5
Determination of the epitope specificity of the monoclonal antibody 33G2.
The detailed epitope specificity on the single amino acid level for the mAb 33G2 was performed using the multiple peptide synthesis technique (PEPSCAN) developed by Geysen et al. (J. Immunol .Methods 102, 259-274, 1987). Peptides were synthesized on po lyethylene rods on which polymers of polyacrylic acid had been formed by irradiation. Polyethylene rods and Fmoc L-amino acids performed as active esthers
(Cambridge Research Biochemicals, UK) were used for synthesis according to instructions of the manufacturer. The N-termi
nals of all peptides were acetylated. As a basis for the mAb 33G2 epitope analysis, the sequence of amino acid residues 1-19 (ESVTEEIAEEDKSVIEEAV) of Ag332 (Mattei, D., Berzins, K., Wahlgren, M., Udomsangpetch, R., Perlmann, P., Griesser, H.W., Scherf, A., Muller-Hill, B., Bonnefoy, S., Guillotte, M., Langsley, G., Pereira da Silva, L. and Mercereau-Puijalon, 0. (1989) Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens.
Parasite Immunol. 11, 15-30) was used, containing sequences of the peptides with the highest reactivity with the mAb
(Udomsangpetch, R., Carlsson, J., Wahlin, B., Holmquist, G., Ozaki, L.S., Scherf, A., Mattei, D., Mercereau-Puijalon, O., Uni, S., Aikawa, M., Berzins, K. and Perlmann, P. (1989) Reactivity of the human monoclonal antibody 33G2 with repeated sequences of three distinct Plasmodium falciparum antigens. J . Immunol . 142, 3620-3626). All possible overlapping heptapeptides, hexpeptides, pentapeptides and tetrapeptides covering the mentioned sequence were synthesized and their reactivity with mAb 33G2 was analysed by ELISA as described by Geysen et al . (J. Immunol. Methods 102, 259-274, 1987). Culture supernatant containing mAb 33G2 (approx. 10 μg/ml), was diluted 1:100. Peptide containing rods were washed in phosphate-buffered saline with 0.05% Tween 20 between all steps in ELISA. Bound antibodies were detected with a rabbit anti-human IgM-alkaline phosphatase conjugate (Sigma, St. Louis, MO) using p-nitrophenyl phosphate, disodium salt (Sigma) as substrate.
The antibody showed reactivity with four heptapeptides corresponding to amino acids 1-7 (ESVTEEI), 2-8 (SVTEEIA), 3-9 (VTEEIAE) and 4-10 (TEEIAEE) (Fig. 1a). When tested against hexapept ides the antibody recognized sequences corresponding to amino acids 2-7 (SVTEEI), 3-8 (VTEEIA) and 4-9 (TEEIAE) (Fig. 1b). Reactivity to pentapeptides was restricted to one peptide, corresponding to amino acids 3-7 (VTEEI) (Fig. 1c), while no reactivity was seen with any of the tetrapeptides (Fig. 1d). When tested against eight heptapeptides
corresponding of the seqυence ESVTEEIA ( amino acids 1-8), where one amino acid residue had been omitted in each peptide, the antibody could not recognize peptides where either V, T, E, E or I had been excluded (Fig. 2).
The mAb 33G2 was anal yzed for reactivity against octapeptides based on the sequence ESVTEEIA, where single amino acid substitutions replaced each residue. Every residue in the parent peptide ESVTEEIA, which corresponds to residue 1-8 of the known sequence of Ag332, was replaced by the most common 20 amino acids (Fig. 3). The first (E), second (S) and last amino acid residue (A) were shown to be replaceable by any other amino acid without loosing the ability of the monoclonal 33G2 to recognize the peptides. A linear, five amino acid, sequence (VTEEI) was shown to consist of amino acids which were either essential or replaceable mainly by amino acids of resembling chemical character. Subsitution of valine (V) by C, F, I, L, P, T, W and Y, and threonine (T) by A, C, I, L, P, S, and V, gave ELISA absorbance values of 20% or more compared to the values obtained with the parent octapeptides. The pair of glutamic acids (E), contained within the epitope, were the most essential residues. The first glutamic acid (E) was totally nonreplaceable while the second glutamic acid (E) was possible to replace with aspartic acid (D), a very conserved replacement, and to some extent with cysteine (C). The last amino acid within the epitope, isoleucine (I), was possible to replace with leucine (L) and valine (V) , two relatively conserved replacements. It could also be replaced to some degree by the positively charged amino acid histidine (H).
Based on the results in the replacement set analysis, pentapeptides corresponding to residue 3-7 of Ag332 were constructed in which one or severala original amino acids had been replaced simultaneously. The results from this assayshowed that it was possible to replace several amino acids within the epitope, simultaneously, without loosing antibody rea ct ivity (Fig. 4). The antibody recognized most of the pep
tides where the modifications were consistent with the results from the replacement set analysis; ITEEI, VAEEI,
IADEI, IADEV, VVEEV and LVEEV. A decrease in antibody reactivity could be seen for some peptides where several amino acids were replaced. The antibody did not react with the pentapeptide, YLDEV, indicating that not all of the reactive single amino acid substitutions can be performed simultaneously and still result in reactive peptides.
Claims (17)
1. A peptide comprising the ammo acid sequence:
U-O-X-glu-Z, wherein:
V is an amino acid residue selected from val and ile:
O is an amino acid residue selected from ala and thr;
X is an amino acid residue selected from asp and glu; and
Z is an amino acid residue selected from ile and val.
2. A peptide comprising the amino acid sequence:
O-X-glu-Z-ala-glu, wherein:
O, X and Z are as defined in claim 1.
3. A peptide according to claim 1, wherein said amino acid sequence is selected from: glu-ser-val-thr-glu-glu-ile;
ser-val-thr-glu-glu-ile-ala;
val-thr-glu-glu-ile-ala-glu;
ser-val-thr-glu-glu-ile;
val-thr-glu-glu-ile-ala;
val-thr-glu-glu-ile;
ile-thr-glu-glu-ile;
val-ala-glu-glu-ile; and
ile-ala-asp-glu-ile.
4. A peptide according to claim 3, wherein said amino acid sequence is:
val-thr-glu-glu-ile.
5. A peptide according to claim 2, wherein said amino acid sequence is selected from: thr-glu-glu-ile-ala-glu-glu; and
thr-glu-glu-ile-ala-glu.
6. A peptide according to any preceding claim for medicinal use.
7. A peptide according to claim 6 for use as an active ingredient in a vaccine.
8. A peptide according to claim 7 for use as an active ingredient in a vaccine against malaria.
9. The use of the peptide according to any of claims 1 to 5 in the preparation of a vaccine.
10. The use of the peptide according to claim 9 in the preparation of a vaccine against malaria.
11. A composition for vaccination against malaria induced by Plasmodium falciparum. comprising a peptide according to any of claims 1 to 5 in admixture with a pharmaceutically acceptable carrier.
12. A composition according to claim 11, wherein said carrier is suitable for parenteral administration.
13. A composition according to claim 11 or 12, wherein said peptide is comprised in a larger molecule, wherein it is present in repeating units.
14. A composition according to claim 11 or 12, wherein said peptide is coupled to a carrier molecule.
15. A composition according to claim 11 or 12, wherein said peptide is coupled to an immunogeniσ carrier.
16. A method of inducing immunity against malaria induced by Plasmodium falciparum. which comprises administering to a person in need of such immunity an effective amount of the composition of any of claims 11 to 15.
17. A method according to claim 16, wherein the administration is constituted by parenteral injection.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9002684 | 1990-08-17 | ||
| SE9002684A SE9002684D0 (en) | 1990-08-17 | 1990-08-17 | NEW PEPTIDES AND THEIR USE |
| PCT/SE1991/000541 WO1992003159A1 (en) | 1990-08-17 | 1991-08-16 | New peptides and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8398591A AU8398591A (en) | 1992-03-17 |
| AU656914B2 true AU656914B2 (en) | 1995-02-23 |
Family
ID=20380175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU83985/91A Ceased AU656914B2 (en) | 1990-08-17 | 1991-08-16 | New peptides and their use |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5609872A (en) |
| EP (1) | EP0544781B1 (en) |
| AT (1) | ATE159172T1 (en) |
| AU (1) | AU656914B2 (en) |
| CA (1) | CA2089660A1 (en) |
| DE (1) | DE69127974T2 (en) |
| SE (1) | SE9002684D0 (en) |
| WO (1) | WO1992003159A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU762945B2 (en) | 1998-08-21 | 2003-07-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant multivalent malarial vaccine against plasmodium falciparum |
| FR2822834B1 (en) * | 2001-04-02 | 2005-02-25 | Flamel Tech Sa | COLLOIDAL SUSPENSION OF NANOPARTICLES BASED ON AMPHIPHILIC COPOLYMERS FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION |
| FR2830447B1 (en) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | MICROPARTICULAR ORAL GALENIC FORM FOR DELAYED AND CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS |
| MXPA04009979A (en) * | 2002-04-09 | 2004-12-13 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin. |
| CA2480826C (en) | 2002-04-09 | 2012-02-07 | Flamel Technologies | Oral pharmaceutical formulation in the form of microcapsule aqueous suspension allowing modified release of active ingredient(s) |
| FR2840614B1 (en) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
| FR2843117B1 (en) * | 2002-07-30 | 2004-10-15 | Flamel Tech Sa | POLYAMINOACIDS FUNCTIONALIZED BY AT LEAST ONE HYDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
| FR2855521B1 (en) * | 2003-05-28 | 2005-08-05 | Flamel Tech Sa | POLYAMINOACIDES FUNCTIONALIZED BY AT LEAST ONE YDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS. |
| FR2860516B1 (en) * | 2003-10-03 | 2006-01-13 | Flamel Tech Sa | TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
| FR2862536B1 (en) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | PHARMACEUTICAL FORMULATIONS FOR THE PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0275196A2 (en) * | 1987-01-14 | 1988-07-20 | Manuel E. Patarroyo | Protein copolymer malaria vaccine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0273971A4 (en) * | 1986-07-17 | 1989-09-19 | Saramane Pty Ltd | SMALL MOLECULAR WEIGHT ANTIGEN OF -i(PLASMODIUM) -i(FALCIPARUM). |
-
1990
- 1990-08-17 SE SE9002684A patent/SE9002684D0/en unknown
-
1991
- 1991-08-16 EP EP91915658A patent/EP0544781B1/en not_active Expired - Lifetime
- 1991-08-16 AT AT91915658T patent/ATE159172T1/en active
- 1991-08-16 CA CA002089660A patent/CA2089660A1/en not_active Abandoned
- 1991-08-16 AU AU83985/91A patent/AU656914B2/en not_active Ceased
- 1991-08-16 US US07/969,305 patent/US5609872A/en not_active Expired - Fee Related
- 1991-08-16 WO PCT/SE1991/000541 patent/WO1992003159A1/en active IP Right Grant
- 1991-08-16 DE DE69127974T patent/DE69127974T2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0275196A2 (en) * | 1987-01-14 | 1988-07-20 | Manuel E. Patarroyo | Protein copolymer malaria vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0544781B1 (en) | 1997-10-15 |
| WO1992003159A1 (en) | 1992-03-05 |
| DE69127974T2 (en) | 1998-02-12 |
| DE69127974D1 (en) | 1997-11-20 |
| ATE159172T1 (en) | 1997-11-15 |
| CA2089660A1 (en) | 1992-02-18 |
| EP0544781A1 (en) | 1993-06-09 |
| SE9002684D0 (en) | 1990-08-17 |
| US5609872A (en) | 1997-03-11 |
| AU8398591A (en) | 1992-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7211256B2 (en) | Plasmodium falciparum antigens inducing protective antibodies | |
| Culvenor et al. | Plasmodium falciparum ring-infected erythrocyte surface antigen is released from merozoite dense granules after erythrocyte invasion | |
| EP0164176B1 (en) | Antigenic proteins and vaccines containing them and protective antibodies directed to them for prevention of coccidiosis caused by eimeria tenella | |
| US5028694A (en) | Antigenic proteins and vaccines containing them for prevention of coccidiosis caused by eimeria Eimeria necatrix and Eimeria tenella | |
| AU656914B2 (en) | New peptides and their use | |
| Ahlborg et al. | Definition of the epitope recognized by the Plasmodium falciparum-reactive human monoclonal antibody 33G2 | |
| AU639588B2 (en) | Malaria vaccine comprising an immunogenic polypeptide | |
| AU603054B2 (en) | Polypeptides comprising repeat units of plasmodium falciparum CS protein, and production thereof | |
| EP0885012A1 (en) | Malaria vaccine based upon the addition of a msa1 peptide | |
| AU584881B2 (en) | Improvements in or relating to the production of malaria vaccines | |
| JP2000506381A (en) | Recombinant protein containing the C-terminal fragment of malaria parasite MSP-1 | |
| Berzins et al. | Antibodies to repeated amino acid sequences in Pf155, a merozoite associated antigen of Plasmodium falciparum | |
| Búa et al. | Trypanosoma cruzi: cellular and antibody response against the parasite in mice immunized with a 19-amino acid synthetic peptide | |
| Kara et al. | Immune response to a synthetic peptide corresponding to an epitope of a parasitophorous vacuole membrane antigen from Plasmodium falciparum. | |
| Millet et al. | Inhibitory activity against sporozoites induced by antibodies directed against nonrepetitive regions of the circumsporozoite protein of Plasmodium vivax | |
| Nguyen-Dinh et al. | Plasmodium fragile: Detection of a ring-infected erythrocyte surface antigen (RESA) | |
| US5116946A (en) | Synthetic, immunologically active peptides useful for the preparation of antimalarial vaccines | |
| Del Giudice et al. | Characterization of murine monoclonal antibodies against a repetitive synthetic peptide from the circumsporozoite protein of the human malaria parasite, Plasmodium falciparum | |
| EP0372019A1 (en) | RHOPTRY MEMBRANE ANTIGEN OF -i(PLASMODIUM FALCIPARUM). | |
| Hockmeyer et al. | Recent efforts in the development of a sporozoite vaccine against human malaria | |
| Kironde et al. | Towards the design of heterovalent anti-malaria vaccines: a hybrid immunogen capable of eliciting immune responses to epitopes of circumsporozoite antigens from two different species of the malaria parasite, Plasmodium. | |
| PT97117A (en) | METHOD FOR PREPARING POLIPEPTIDIC DERIVATIVES AND IMMUNOGENIC COMPOSITIONS CONTAINING THEM | |
| KARA et al. | Plasmodium falciparum | |
| PT100757A (en) | POLYPEPTIDES FOR INDUCING "IN VIVO" ANTIBODIES ABLE TO INHIBIT THE INVASION OF RED GLOBULES BY MERZOITOS OF "P. FALCIPARUM", APARENTED PRODUCTS AND ITS APPLICATION IN THE PRODUCTION OF VACCINATION COMPOSITIONS | |
| DE | Plasmodium falciparum Ring-Infected Erythrocyte Surface Antigen Is Released from Merozoite Dense Granules |